Novartis Considering Sale or Separation of Sandoz Business

Novartis Considering Sale or Separation of Sandoz Business

August 2022

In October 2021, Novartis launched a strategic review of the Sandoz division, an important part of which is the Slovenian Lek as a development center.

As Novartis said in the press release, the review will explore all options, ranging from retaining the business to separation, in order to determine how to best maximize value for the shareholders. They will take the time to decide by the end of 2022.

Sandoz is one of the largest generics entities in the world and Novartis’ leading business unit for the development of biosimilar products. It accounts for about 18% of the overall company’s sales.

At the end of August 2022, Novartis announced its intention to separate Sandoz, its generics and biosimilars division into a new publicly traded standalone company, by way of a 100% spin-off.

The spin-off aims to maximize shareholder value by creating the #1 European generics company1 and a global leader in biosimilars, allowing Novartis shareholders to participate fully in the potential future upside for both Sandoz and Novartis Innovative Medicines. The transaction is expected to be completed in H2 2023.

August 2022

In October 2021, Novartis launched a strategic review of the Sandoz division, an important part of which is the Slovenian Lek as a development center.

As Novartis said in the press release, the review will explore all options, ranging from retaining the business to separation, in order to determine how to best maximize value for the shareholders. They will take the time to decide by the end of 2022.

Sandoz is one of the largest generics entities in the world and Novartis’ leading business unit for the development of biosimilar products. It accounts for about 18% of the overall company’s sales.

At the end of August 2022, Novartis announced its intention to separate Sandoz, its generics and biosimilars division into a new publicly traded standalone company, by way of a 100% spin-off.

The spin-off aims to maximize shareholder value by creating the #1 European generics company1 and a global leader in biosimilars, allowing Novartis shareholders to participate fully in the potential future upside for both Sandoz and Novartis Innovative Medicines. The transaction is expected to be completed in H2 2023.